{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-098487","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2025-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.187300+00:00","generated_at":"2026-05-17T04:06:44.967190+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apogee (APGE) raises $323M, updates APG777 atopic dermatitis and asthma trials","bullets":["Offering of 6.95M shares at $41 plus pre-funded warrants and full underwriter option exercise, net proceeds ~$323.3M.","APG777 APEX atopic dermatitis trial enrollment increased to 320 patients; Part B enrollment expected by year-end 2025.","Topline maintenance data from APEX Part A expected Q1 2026; 16-week induction data from Part B in Q2 2026.","Phase 1b asthma topline data for APG777 expected in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-098487","json":"https://secwatch.observer/filing/0001104659-25-098487.json","markdown":"https://secwatch.observer/filing/0001104659-25-098487.md","text":"https://secwatch.observer/filing/0001104659-25-098487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925098487/0001104659-25-098487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925098487/tm2528385d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:06:44.967190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}